AU2021286196A1 - High dose and low volume botulinum toxin treatment of facial wrinkles - Google Patents

High dose and low volume botulinum toxin treatment of facial wrinkles Download PDF

Info

Publication number
AU2021286196A1
AU2021286196A1 AU2021286196A AU2021286196A AU2021286196A1 AU 2021286196 A1 AU2021286196 A1 AU 2021286196A1 AU 2021286196 A AU2021286196 A AU 2021286196A AU 2021286196 A AU2021286196 A AU 2021286196A AU 2021286196 A1 AU2021286196 A1 AU 2021286196A1
Authority
AU
Australia
Prior art keywords
botulinum toxin
lines
treatment
dose
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021286196A
Other languages
English (en)
Inventor
Thorin Geister
Gudrun Klein
Irena Pulte
Susanna ROLL
Meik Sladek
Petra WEISSENBERGER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merz Pharma GmbH and Co KGaA
Original Assignee
Merz Pharma GmbH and Co KGaA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=71016459&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2021286196(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merz Pharma GmbH and Co KGaA filed Critical Merz Pharma GmbH and Co KGaA
Publication of AU2021286196A1 publication Critical patent/AU2021286196A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Birds (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AU2021286196A 2020-06-05 2021-06-04 High dose and low volume botulinum toxin treatment of facial wrinkles Pending AU2021286196A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20178574.8 2020-06-05
EP20178574 2020-06-05
PCT/EP2021/064986 WO2021245223A1 (en) 2020-06-05 2021-06-04 High dose and low volume botulinum toxin treatment of facial wrinkles

Publications (1)

Publication Number Publication Date
AU2021286196A1 true AU2021286196A1 (en) 2022-12-01

Family

ID=71016459

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021286196A Pending AU2021286196A1 (en) 2020-06-05 2021-06-04 High dose and low volume botulinum toxin treatment of facial wrinkles

Country Status (13)

Country Link
US (1) US12599550B2 (https=)
EP (2) EP4161562B1 (https=)
JP (1) JP2023529095A (https=)
KR (1) KR20230020961A (https=)
CN (1) CN115666629A (https=)
AU (1) AU2021286196A1 (https=)
BR (1) BR112022023413A2 (https=)
CA (1) CA3177835A1 (https=)
ES (1) ES3013130T3 (https=)
IL (1) IL298399A (https=)
MX (1) MX2022014564A (https=)
TW (1) TW202214211A (https=)
WO (1) WO2021245223A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL298399A (en) 2020-06-05 2023-01-01 Merz Pharma Gmbh & Co Kgaa Treatment of facial wrinkles with the botulinum toxin in high dose and low volume
KR20240169045A (ko) * 2022-04-01 2024-12-02 충칭 클라루비스 파마슈티컬 컴퍼니 리미티드 보툴리눔 독소 단백질 조성물, 이의 제조 방법 및 용도
EP4626556A1 (en) * 2022-11-28 2025-10-08 Merz Pharma GmbH & Co. KGaA High concentration botulinum toxin treatment for neck rejuvenation
WO2025231403A1 (en) * 2024-05-03 2025-11-06 Revivity Pharma Corporation Methods of administering and manufacturing toxic compounds

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19925739A1 (de) 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US7691394B2 (en) * 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
DE10333317A1 (de) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
BRPI0513850A (pt) 2004-07-26 2008-05-20 Merz Pharma Gmbh & Co Kgaa composição terapêutica com uma neurotoxina botulìnica
EP2072039A1 (en) * 2007-12-21 2009-06-24 Merz Pharma GmbH & Co.KGaA Use of a neurotoxic component of Clostridium botulinum toxin complex to reduce or prevent side effects
PL2271670T3 (pl) 2008-03-14 2015-05-29 Allergan Inc Testy aktywności serotypu A toksyny botulinowej oparte na immunologii
HUE037509T2 (hu) * 2011-09-29 2018-09-28 Cellsnap Llc Készítmények és eljárások toxigenicitás meghatározására
PL3014267T3 (pl) * 2013-06-28 2019-05-31 Merz Pharma Gmbh & Co Kgaa Środki i sposoby określania aktywności biologicznej polipeptydów neurotoksyny w komórkach
US9480731B2 (en) * 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
SG11202005239YA (en) * 2017-12-04 2020-07-29 Revance Therapeutics Inc Injectable botulinum toxin formulations and methods of use thereof having high response rate and long effect duration
IL298399A (en) 2020-06-05 2023-01-01 Merz Pharma Gmbh & Co Kgaa Treatment of facial wrinkles with the botulinum toxin in high dose and low volume

Also Published As

Publication number Publication date
JP2023529095A (ja) 2023-07-07
CN115666629A (zh) 2023-01-31
EP4161562A1 (en) 2023-04-12
MX2022014564A (es) 2022-12-15
EP4467202A3 (en) 2025-02-19
WO2021245223A1 (en) 2021-12-09
EP4161562B1 (en) 2024-11-20
KR20230020961A (ko) 2023-02-13
EP4467202A2 (en) 2024-11-27
ES3013130T3 (en) 2025-04-11
TW202214211A (zh) 2022-04-16
BR112022023413A2 (pt) 2022-12-20
IL298399A (en) 2023-01-01
CA3177835A1 (en) 2021-12-09
US20230329996A1 (en) 2023-10-19
US12599550B2 (en) 2026-04-14

Similar Documents

Publication Publication Date Title
US12599550B2 (en) High dose and low volume botulinum toxin treatment of facial wrinkles
US12144847B2 (en) Non-protein clostridial toxin compositions
JP6235176B2 (ja) 非タンパク質安定化クロストリジウム毒素医薬組成物
JP5690785B2 (ja) 改良されたボツリヌス毒素組成物
US20230158129A1 (en) Clostridial toxin - hyaluronic acid compositions
AU2016343748A1 (en) Injectable botulinum toxin formulations and methods of use thereof having long duration of therapeutic or cosmetic effect
KR102835193B1 (ko) 보툴리눔 톡신 a형 복합체, 이의 제제 및 이의 사용 방법
RU2835617C1 (ru) Лечение морщин на лице высокой дозой и малым объемом ботулинического токсина
Boone et al. Botulinum toxin in aesthetic medicine
JP2011157331A (ja) 高用量投与が可能なボツリヌス毒素製剤
HK40085901A (en) High dose and low volume botulinum toxin treatment of facial wrinkles
US20240207303A1 (en) mNA-based Delivery of Botulinum Toxin
US20240000905A1 (en) Polymeric nanoparticle compositions for encapsulation and sustained release of neuromodulators
AU2016204034A1 (en) Non-protein stabilized clostridial toxin pharmaceutical compositions
CN116249513A (zh) 稳定性改善的重组肉毒毒素轻链蛋白组合物
KR20240032688A (ko) 내성 발현이 감소된 보툴리눔 독소 제제 및 이와 관련된 방법